key: cord-1051001-g22t6xtb
authors: Zhou, Yadi; Hou, Yuan; Shen, Jiayu; Kallianpur, Asha; Zein, Joe; Culver, Daniel A.; Farha, Samar; Comhair, Suzy; Fiocchi, Claudio; Gack, Michaela U.; Mehra, Reena; Stappenbeck, Thaddeus; Chan, Timothy; Eng, Charis; Jung, Jae U.; Jehi, Lara; Erzurum, Serpil; Cheng, Feixiong
title: A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19
date: 2020-07-02
journal: ChemRxiv
DOI: 10.26434/chemrxiv.12579137
sha: 6b4138b96bd01dbbaf99bbc8285bf695c5a81659
doc_id: 1051001
cord_uid: g22t6xtb

The global Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to unprecedented social and economic consequences. The risk of morbidity and mortality due to COVID-19 increases dramatically in the presence of co-existing medical conditions while the underlying mechanisms remain unclear. Furthermore, there are no proven effective therapies for COVID-19. This study aims to identify SARS-CoV-2 pathogenesis, diseases manifestations, and COVID-19 therapies using network medicine methodologies along with clinical and multi-omics observations. We incorporate SARS-CoV-2 virus-host protein-protein interactions, transcriptomics, and proteomics into the human interactome. Network proximity measure revealed underlying pathogenesis for broad COVID-19-associated manifestations. Multi-modal analyses of single-cell RNA-sequencing data showed that co-expression of ACE2 and TMPRSS2 was elevated in absorptive enterocytes from the inflamed ileal tissues of Crohn's disease patients compared to uninflamed tissues, revealing shared pathobiology by COVID-19 and inflammatory bowel disease. Integrative analyses of metabolomics and transcriptomics (bulk and single-cell) data from asthma patients indicated that COVID-19 shared intermediate inflammatory endophenotypes with asthma (including IRAK3 and ADRB2). To prioritize potential treatment, we combined network-based prediction and propensity score (PS) matching observational study of 18,118 patients from a COVID-19 registry. We identified that melatonin (odds ratio (OR) = 0.36, 95% confidence interval (CI) 0.22-0.59) was associated with 64% reduced likelihood of a positive laboratory test result for SARS-CoV-2. Using PS-matching user active comparator design, melatonin was associated with 54% reduced likelihood of SARS-CoV-2 positive test result compared to angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (OR = 0.46, 95% CI 0.24-0.86).

The ongoing global Coronavirus Disease 2019 pandemic has led to 5 million confirmed cases and 327,000 deaths worldwide as of May 21, 2020. The United States alone has 1.58 million confirmed cases with a death toll of more than 93,000. Several retrospective studies have reported the clinical characteristics of individuals with symptomatic COVID-19 infection, and an emerging theme has been the significantly higher risk of morbidity and mortality among individuals with one or more comorbid health conditions, such as hypertension, asthma, diabetes mellitus, cardiovascular or cerebrovascular disease, chronic kidney disease and malignancy (1-6). However, these retrospective clinical studies are limited by small sample sizes and unmeasured confounders, leaving the underlying patho-mechanisms largely unknown. More specifically, it is unclear whether associations of disease manifestations and COVID-19 severity are merely a reflection of poorer health in general, or a clue to shared pathobiological mechanisms.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, is an enveloped virus that carries a single-stranded positive-sense RNA genome (6, 7) . SARS-CoV-2 is a newly discovered member of the coronavirus (CoV) family (8) . SARS-CoV-2 enters host cells via binding with its spike protein to the angiotensin converting enzyme 2 (ACE2) receptor on the surfaces of many cell types (9) . This binding is primed by transmembrane protease serine 2 (TMPRSS2) (9) and the host cell protease furin (10) (Fig. 1A) .

Studies have shown that ACE2 and TMPRSS2 are highly co-expressed in alveolar type II (AT2) epithelial cells in the lung (11) , nasal mucosa (12) , bronchial secretory cells (13) , and absorptive enterocytes in the ileum (14) . Yet, much remains to be learned on how these critical human proteins involved in the infection and replication of SARS-CoV-2 are associated with various (15) (16) (17) . Studies using transcriptomics (18) , proteomics (19) , and interactomics (20) (PPIs) methods have contributed to a better understanding of the SARS-CoV-2-host interactome, which enabled the investigation of the complications and comorbidities of SARS-CoV-2 and a facilitated search for effective treatment (Fig. 1B) .

Major efforts are underway to develop safe and effective drugs to treat COVID- 19: preventive and therapeutic strategies currently being explored include vaccination, SARS-CoV-2-specific antibody, novel nucleoside analogues such as remdesivir, and repurposed drugs (21) (22) (23) (24) (25) . The development of vaccination and antibody therapies takes significantly longer compared to drug repurposing. Many existing drugs are currently or have been tested in clinical trials, such as the antimalarial drug hydroxychloroquine and protease inhibitor combination lopinavir/ritonavir (26, 27) . However, early results from these trials have not yet shown significant clinical benefits for COVID-19 patients (26, 27) . We recently evaluated more than 2,000 FDA approved/investigational drugs using network-based method and prioritized 16 drug candidates and 3 drug combinations for COVID-19 (28) . Yet, the answer to the key question why an approved drug originally documented for other diseases can be repurposed for COVID-19 remains unclear. One possible explanation is that COVID-19 shares common disease pathobiology or functional pathways elucidated by the human PPIs (24, 28, 29) . Systematic In this study, we present an integrative network medicine platform that quantifies the association of COVID-19 with other diseases across six categories, including autoimmune, malignant, cardiovascular, metabolic, neurological, and pulmonary (Fig. 1C) . The rationale for these analyses rests on the notions that (i) the proteins that functionally associate with disease (such as are localized in the corresponding subnetwork within the comprehensive human PPI network (24, (29) (30) (31) ; and (ii) proteins that are associated with a specific disease may be directly targeted by the virus or are in the close vicinity of virus host proteins. We first performed network analysis followed by single-cell RNA-Seq data analysis to identify the underlying pathobiological relationships between COVID-19 and its associated comorbidities.

Secondly, we used our network-medicine findings and patient data from a large COVID-19

clinical registry database to identify and prioritize existing FDA-approved drugs as potential COVID-19 drug candidates (Fig. 1D) .

We assembled four host gene/protein sets for SARS-CoV-2 (see Methods) ( Table S1) We first performed functional enrichment analyses for the five different data sets. We found that while these data sets share several common pathways and ontology terms ( Fig. 2A) ,

such as phagosome, measles, apoptosis, NF-kappa B signaling pathway, neutrophil-related immunity, apoptotic processes, virus transport, viral genome replication, and response to interferon, they differ considerably in terms of their most significantly enriched pathways ( Fig.   S1 -S5). This is especially noticeable for SARS2-DEP and SARS2-PPI. While SARS2-DEG ( Fig.   S1 ) and HCoV-PPI ( Fig. S3) show more enrichment in immune responses and viral pathways;

SARS2-DEP ( Fig. S2) is more related to various cellular metabolic pathways; and SARS2-PPI ( Fig. S4 ) is more enriched in DNA replication, RNA transcription, and protein translation. These observations suggest that these different SARS-CoV-2 data sets capture complementary aspects of the biological and cellular states of the viral life cycle and host immunity. Therefore, building a global virus-host map (including interactome, transcriptome, and proteome) that incorporates data from transcriptomics, proteomics, and physical virus-host PPIs are essential for a better understanding of the pathogenesis of COVID-19. This global virus-host map for SARS-CoV-2

can offer a more complete picture of the interconnected functional pathways involved in viral pathogenesis, thereby facilitating discovery of therapeutic targets.

In addition to identifying the functions that these data sets represent, we next characterized the network patterns (node degree in the human PPI network) and bioinformatics features of these SARS-CoV-2 data sets, including ratio of non-synonymous to synonymous substitutions Z h o u e t a l . 2 0 2 0 d r a f t (dN/dS), evolutionary rate ratio, and lung expression specificity (Fig. 2B-G and Fig. S6 ). To find common as well as unique network and bioinformatic characteristics of SARS-CoV-2, we further compiled four additional virus-host gene/protein networks identified by different methods for comparisons (Table S2) identified by co-immunoprecipitation and liquid chromatography-mass spectrometry (Co-IP+LC/MS). We found that host proteins in PanCoV-PPI (Fig. 2B ) and four other data sets (SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI) (Fig. S6) were more likely to be highly connected (high degree or connectivity) in the human PPI network, including several hubs, such as JUN, XPO1, MOV10, NPM1, VCP, and HNRNPA1. PanCoV-PPI has a comparable degree distribution with host proteins/genes identified by viORFs and Co-IP+LC/MS, although being marginally lower than that identified by RNAi and gene-trap insertional mutagenesis assay (Fig. 2F) .

Expression patterns of genes in a specific disease-related tissue play crucial role for elucidation of disease pathogenesis and drug discovery (24, 29) . Given the major impact of SARS-CoV-2 on pulmonary function and lung injury (1), we inspected the lung-specific expression of genes in PanCoV-PPI using a Z score measure compared to other 30 tissues from the GTEx database (see Methods). We found that most host genes for SARS-CoV-2 have high expression in lung (Fig. 2E , Table S1 ) compared to other tissues; yet, ACE2 has a low expression in lung compared to other tissues. A recent study showed that ACE2 was primarily Z h o u e t a l . 2 0 2 0 d r a f t expressed in the epithelial cells in lungs, and only 3.8% of alveolar type 2 pneumocytes expressed both ACE2 and TMPRSS2, but it is significantly upregulated in smokers and 24-48 hours following SARS-CoV-2 infection (11, 32) . Another study also showed that despite relatively low expression of ACE2 in the lung, ACE2 was expressed in multiple epithelial cell types along the airway (12) . Therefore, it is important to understand the cell type-specific SARS-CoV-2 pathogenesis at single cell levels.

To inspect the evolutionary factors underlying the SARS-CoV-2-human PPIs, we investigated the selective pressure and evolutionary rates quantified by the non-synonymous versus synonymous substitution rate ratios (dN/dS ratios, see Methods) using human-mouse orthologous gene pairs. We found that PanCoV-PPI has a stronger purifying selection (lower dN/dS ratios (Fig. 2C ) and evolutionary rate ratio (Fig. 2D) ) compared to the same number of random genes. PanCoV-PPI is also comparable to other four virus-host genes/proteins identified by different assays (Fig. 2F, G) in terms of node degrees and dN/dS ratios. Altogether, these observations suggest that the virus-host PPIs assembled in this study offer a high-quality interactome map for SARS-CoV-2 for identifying pathogenesis and potential treatments for COVID-19.

To inspect shared viral pathways across different viruses and SARS-CoV-2, we further performed network overlap analysis of PanCoV-PPI with 712 host genes across 10 types of other viruses identified by gene-trap insertional mutagenesis assays (25) . We found a significant overlap of the SARS-CoV-2 host proteins with non-coronaviruses (P < 0.002, Fisher's exact test, d r a f t family of GTPases, is connected to SARS-CoV-2, cowpox, and HSV-2 as well. RHOA has been reported to be involved in multiple human diseases, including cardiovascular disease (33) and

cancer (34) . These observations indicate possible disease manifestations associated with SARS-CoV-2.

Investigation of the relationships between human host proteins targeted by SARS-CoV-2 and disease susceptibility genes may offer crucial information for identifying COVID-19-associated disease manifestations. We thus inspected the overlap between SARS-CoV-2 host genes/proteins and the susceptibility gene sets implicated in different diseases and biological events (Fig. 2I ).

We found that host genes/proteins targeted by SARS-CoV-2 are significantly enriched in Mendelian disease (P = 0.002, Fisher's exact test), orphan disease (P = 0.044), and cancer (P < 0.001). Mechanistically, SARS-CoV-2 target host genes are significantly enriched in cell cycle genes (P < 0.001) and innate immune genes (P < 0.001).

Using the five SARS-CoV-2 host gene/protein sets, we next tried to identify potential COVID-19 comorbidities. To achieve this, we assembled the disease-protein network of COVID-19 and six disease categories (Table S3) . For cancer, the driver genes for pan-cancer and individual cancer types were retrieved from the Cancer Gene Census (35) and a previous study (36) . For autoimmune, pulmonary, neurological, cardiovascular, and metabolic categories, we extracted their associated genes/proteins from the Human Gene Mutation Database (37) .

Using the disease-protein network together with the SARS2-PPI (SARS-CoV-2 virus-host interactome) and HCoV-PPI (HCoV-host interactome) sets, we examined their overall connectivity in the human PPI network (Fig. 3A Shown in Fig. 3A , these diseases can be targeted directly or interact with the targets of SARS-CoV-2 or other HCoVs. For example, among the four chronic obstructive pulmonary disease (COPD) associated proteins shown in the network, TGFB1 is the direct target of HCoV-229E, and all four proteins (TGFB1, DEFB1, SNAI1, and ADAM33) interact with at least one SARS-CoV-2 viral protein target. The risk of various cardiovascular diseases was found to be increased in COVID-19 patients, including heart block, coronary artery disease, and congestive heart failure, and arrhythmia, which is consistent with clinically reported myocardial injury (38) and cardiac arrest (39) . These observations reveal common network relationship between COVID-19 and human diseases (Fig. 3A) . We then performed meta-analysis of 34 COVID-19

clinical studies ( d r a f t were used to evaluate the heterogeneity among studies. We found that 8 comorbidities have significantly higher risks in severe COVID-19 patients (Fig. 3B) . The overall pooled risk ratio of COPD was 4.33 (95% confidence interval (CI) 2.42-7.74, P = 0.001) in 12 low heterogeneous clinical studies (I 2 = 0.0%, P = 0.6). The COVID-19 patients with cardiovascular diseases have a risk ratio of 3.87 (95% CI 1.97-7.59, P = 0.001), and there was a slightly higher heterogeneity across the 13 studies (I 2 = 57.6%, P = 0.005). Patients with stroke, diabetes, chronic kidney disease, hypertension, cancer, and history of smoking were also found with higher risk ratios of severe COVID-19. We next turned to quantify the network-based relationships between COVID-19 and human diseases under the human interactome model using the network proximity measure.

We systematically evaluated the network-based relationships of the 64 diseases across the 6 categories to COVID-19 (Fig. 4A) . We used the state-of-the-art network proximity measure to evaluate the connectivity and the closeness of the disease proteins and SARS-CoV-2 host proteins, taking the topology of the human interactome network into consideration. To test the significance of the proximity, Z scores and P values were calculated based on the permutation tests and are shown in Fig. 4A . We found that each disease-disease pair has a well-defined network-based footprint. If the footprint between COVID-19 module and another disease module is significantly close (low Z score and P < 0.05), the magnitude of the proximity is indictive of their biological relationship: closer network proximity (Fig. 4A ) of SARS-CoV-2 host genes/proteins with a disease module indicates higher potential of manifestation between COVID-19 and a specific disease. We first noticed that immunological, pulmonary, and Z h o u e t a l . 2 0 2 0 d r a f t neurological diseases show significant proximity to SARS-CoV-2 data sets more frequently than do cancer, cardiovascular, and metabolic diseases. Some diseases have significant proximities to more than one SARS-CoV-2 data sets, most notably inflammatory bowel disease (IBD), attention-deficit/hyperactivity disorder, and stroke, which achieved significant P value for all five SARS-CoV-2 protein sets. Pulmonary diseases, including COPD, lung injury, pulmonary fibrosis, and respiratory failure, achieved four significant proximities. Some diseases have significant proximities to certain SARS-CoV-2 data sets, indicating associations at certain levels, e.g., asthma (transcriptomic), respiratory distress syndrome (proteomic), and hypertension.

Network visualization can further show the connections between SARS-CoV-2 and other diseases, for example, respiratory distress syndrome ( Fig. 4B) , sepsis (Fig. 4C) , and COPD ( Fig.   S7 ). We found that multiple SARS-CoV-2 host proteins are directly connected with the diseaseassociated proteins (Fig. 4B ). ABCA3 is a lipid transporter located in the outer membrane of lamellar bodies in AT2 cells; the mutations of the ABCA3 gene can disrupt pulmonary surfactant homeostasis and lead to inherited pulmonary diseases (40) . Another membrane surface protein, the pulmonary-associated surfactant protein C encoded by SFTPC, can cause lung injury when misfolded (41) . For sepsis, we noticed several inflammatory and immune-related proteins, such as IRAK1, IRAK3, IKBKB, and STAT3, suggesting overlap of the inflammatory response activated in COVID-19 and sepsis (Fig. 4C) . It has been reported that an overzealous production of certain cytokines, such as IL-6, caused by dysregulation of innate immune responses to SARS-CoV-2 infection can result in a 'cytokine storm', better known as cytokine release syndrome (CRS) (42) . The potential prognoses of acute respiratory distress syndrome and sepsis using IL-6 expression levels were also established (43) (44) (45) . IL-6 also has a significantly increased expression level in the human bronchial epithelial cells infected with SARS-CoV-2 from the Z h o u e t a l . 2 0 2 0 d r a f t SARS2-DEG data set (18) . In addition, it is also potentially affected by SARS-CoV-2 through multiple PPIs (Fig. 4B, 4C , IL-6 neighbors), such as IL-6R, endophilin A1 (encoded by SH3GL2), and parathyroid hormone like hormone (encoded by PTHLH). Our random effects meta-analysis of 5 clinical studies of COVID-19 revealed that there was an increase of IL-6 levels in severe COVID-19 patients compared to non-severe COVID-19 patients (Fig. 4D) As an illustration of the shared pathobiology and inflammatory pathways of COVID-19

with various disease manifestations ( Fig. 4) , we next turned to focus on two inflammation-driven diseases, asthma and IBD.

Patients with severe COVID-19 symptoms showed a higher prevalence of dyspnea ( Fig. S8A , P < 0.001). To understand associations between COVID-19 and respiratory disease (including asthma), we adopted a multi-modal analysis utilizing metabolomics and transcriptomics data from two previous asthma cohorts (see Methods) under the human interactome network model. showed that glucose metabolism plays a key role in influenza A-regulated cytokine storm (47) .

The unique plasma metabolome of asthmatics versus healthy controls also suggests activated inflammatory and immune pathways (48) . Therefore, in addition to PPIs, we also integrated metabolomics data generated in a previously assembled asthma cohort (49) . By matching the enzymes of the differential metabolites and the proteins in the PPI network, we found three key metabolites, including arachidonate, L-arginine, and L-citrulline. L-arginine and L-citrulline were decreased in the sera of COVID-19 patients (50) . A previous study showed that these metabolites were also decreased in asthma patients (49) . Arachidonate, the precursor of a variety of products that regulate inflammatory pathways (51) , was found to have an increased level in the inflamed airways of asthmatics (52) . Arachidonate can be converted by 5-lipoxygenase encoded by ALOX5 to leukotriene, which is release during an asthma attack and is responsible for the bronchoconstriction (53).

We further examined the DEGs from two asthma cohorts from the Severe Asthma

Research Program (54, 55) . Utilizing two bulk RNA-Seq data sets from asthma patients and healthy controls, we identified elevated expression of IRAK3 and ADRB2 in SARS-CoV-2 infected human bronchial epithelial cells (Fig. 5B) . IRAK-M, encoded by IRAK3, regulates the toll-like receptor/interleukin (IL)-1 receptor pathway and NF-κB pathway, and IRAK3 was identified as an asthma susceptibility gene (56) . ADRB2 encodes the beta 2-adrenergic receptor.

The polymorphisms of ADRB2 (p.Arg16Gly and p.Gln27Glu) increased the risk of asthma occurrence, and p.Gln27Glu was associated with asthma severity (57) . Altogether, altered IRAK3 Z h o u e t a l . 2 0 2 0 d r a f t and ADRB2 may explain relationships between COVID-19 and asthma, though these findings require experimental and clinically validation in patients with these disorders.

To understand expressions of the proteins in the asthma-COVID-19 network across different cell types, especially those cells which express ACE2, we analyzed the single-cell RNA-Seq data from bronchial epithelium (Fig. 5C ) and lung ( Fig. 5F ) (13) . Consistent with previous studies, ACE2 and TMPRSS2 have a relatively higher expression in a subtype of the secretory cells (secretory 3 cells), compared to other bronchial epithelial cell types (Fig. 5D, Fig.   S8C -F). In the lung, ACE2 and TMPRSS2 have a relatively higher expression in AT2 cells (Fig.   5G, Fig. S8H-K) . We further examined the expression of the genes in the asthma-COVID-19 network (Fig. 5A ) in these cell types (Fig. S9) . Several genes were also more highly expressed in secretory 3 (Fig. 5E , ALOX5, IRAK3, ADRB2, TNIP1, BID, CXCL5, and NFKBIZ) and in AT2

( Fig. 5H , CFTR, NFKBIA, NFKBIZ, and TNC), than in other cell types. IRAK3 and ADRB2 are among the six overlapped genes, potentially implicating IRAK3 and ADRB2 in COVID-19associated asthma at the single cell level as well.

It has been shown that human small intestine is an additional SARS-CoV-2 target organ using confocal-and electron-microscopy (58) . Diarrhea is now well-described as an occasional presenting symptom of COVID-19 (59) . Our network proximity analysis showed a significant association of COVID-19 and IBD across all five SARS-CoV-2 data sets (Fig. 4A ). In addition, severe COVID-19 patients had higher risks of abdominal pain and diarrhea (Fig. 6A, Fig. S10 ).

To understand these associations at the cellular level, we integrated network analysis and singlecell RNA-Seq analysis using publicly available data (60) . As shown in Fig. 6B , although only Z h o u e t a l . 2 0 2 0 d r a f t one IBD-associated protein, HEATR3, was found to be the target of the SARS-CoV-2 protein

Orf7a, other IBD-associated proteins showed enriched number of connections to the SARS-CoV-2 target proteins (Fig. 6I , blue bars).

Using single-cell data from the ileum (distal small bowel) in Crohn's disease patients (60) , we found that ACE2 and TMPRSS2 had low to undetectable expression in the non-epithelial cells (Fig. 6C, 6E, Fig. S11A-E) . However, they showed higher expression levels in the epithelial cells, especially absorptive enterocytes (Fig. 6D, 6F, Fig. S11F-J) . We further found that both ACE2 and TMPRSS2 had elevated expression levels in inflamed cells compared to uninflamed cells in the absorptive enterocytes (Fig. 6G, Fig. S11K , L). In absorptive enterocytes expressing ACE2, the expression of ACE2 was significantly increased (Fig. 6H , P = 0.016) in the inflamed ileal tissues of Crohn's disease patients compared to uninflamed tissues. These observations prompted us to investigate the co-expression of the network genes in the absorptive enterocytes (Fig. 6I) . Several genes showed elevated co-expression with ACE2 in inflamed cells,

including XIAP, SMAD3, DLG5, SLC15A1, RAC1, STOM, RAB18, and AKAP8.

We next turned to highlight two potential associations between COVID-19 and IBD.

First, SARS-CoV-2 protein Orf7a can directly interact with HEATR3, whose variant was shown to be associated with increased risks of IBD by genome-wide association study (61) . Second, SARS-CoV-2 infection may impact RAC1 signal transduction pathways. RAC proteins play important roles in many inflammatory pathways, and their dysregulation can be pathogenic.

Increased RAC1 expression by single nucleotide polymorphisms promotes an inflammatory response in the colon (62) . Mercaptopurine, an effective treatment for IBD, was found to lower RAC1 expression in IBD patients (63) . Since our results show that RAC1 and ACE2 had higher co-expression in inflamed enterocytes (Fig. 6I) , it is highly possible that these inflamed cells are . 6B) . Notably STOM was also highly co-expressed with ACE2 in inflamed cells compared to uninflamed cells (Fig. 6I) .

Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks. In addition, drug repurposing efforts may also reveal unrecognized biological connections between diseases that existing drugs treat and COVID-19. For example, the aforementioned anti-inflammatory drugs, tocilizumab and sarilumab that are now being tested for COVID-19 are originally used for rheumatoid arthritis.

Although not significant, our network proximity results show that rheumatoid arthritis have small network proximities (negative Z scores) across all five SARS-CoV-2 data sets (Fig. 4A) .

Another drug, the thiopurine mercaptopurine which has been used to treat IBD (64) , was one of the top repurposable drugs for COVID-19 proposed in our previous work (28) .

Therefore, we next performed network-based drug repurposing using the existing knowledge of the drug-target network and the global map of the SARS-CoV-2 interactome built in this study. The basis for the network-based drug repurposing methodologies rests on the observation that for a drug with multiple targets to be effective against a disease, its target proteins should be within or in the immediate vicinity of the corresponding subnetwork of the disease in the human interactome, as we have demonstrated in multiple diseases previously (24, 29) . Using our state-of-the-art network proximity framework, we measured the "closest" In total, we computationally identified 34 drugs that were associated (Z < -1.5 and P < 0.05, permutation test) with the SARS-CoV-2 data sets (SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI). These drugs were significantly proximal to two or more SARS-CoV-2 host protein sets (Fig. 7A, Table S5 ). We manually curated their reported antiviral profiles. The disease categories that these drugs have been used to treat are also shown in the figure. Ten drugs have been used to treat respiratory-related diseases, and the most common categories for these drugs are antibiotic and β2 agonist. The next most popular disease category is cardiovascular diseases, for which seven drugs were predicted. Among the 34 drugs, three drugs achieved significant network proximity with all four SARS-CoV-2 data sets investigated here. These Applying these criteria resulted in identifying melatonin, a physiologic hormone common to many living organisms.

A retrospective COVID-19 cohort analysis was conducted to validate the potential prevention effect of melatonin (Fig. 7B) (71) . We further performed an observational study for three cohorts using user active comparator design and PS adjustment for confounding factors as described in our previous study (24) . We found that melatonin usage was associated (Fig. 7B) . Altogether, networkbased prediction (Fig. 7A) and multiple observational analyses (Fig. 7B) suggest potential of treatment for COVID-19 by melatonin; yet, randomized controlled clinically trials are urgently needed to test meaningfully the effect of melatonin for COVID-19 further.

Recent studies indicated that SARS-CoV-2 infection was detected in multiple organs in addition to lungs, including heart, pharynx, liver, kidneys, brain, and intestine (58, 72) . SARS-CoV-2 RNA was also found in patient stool (73) . Therefore, investigation of how SARS-CoV-2 associates with other diseases could help reveal and understand its impact on systems and organs in addition to lungs. In this study, we systematically evaluated 64 diseases across 6 categories for their potential manifestations with COVID-19. We started with assembling and characterizing five SARS-CoV-2 data sets representing different cellular event levels including transcriptome, proteome, and interactome. Using state-of-the-art network proximity measure, we identified broad manifestations (such as autoimmune, neurological, and pulmonary, d r a f t enterocytes in ileum. We examined the expression of asthma-and IBD-associated genes in their relevant cell types. Combining these results with the results of differential expression analysis, network connectivity, and differential metabolites, we identified several key pathogenic pathways (including IRAK3 and ADRB2) that can be altered by the viral infection for asthma.

For asthma, our network-based findings suggest several possible shared pathobiological pathways associated with COVID-19. First, SARS-CoV-2 infection might alter the expression of several key inflammatory genes: IRAK3, which is associated with asthma (56, 74, 75) ; ADRB2, which is an essential genetic factor for asthma (57, 76) ; and NFKBIA, which showed critical transcriptional responses in childhood asthma (77) . These genes show high expression in secretory 3 and AT2 cell types, suggesting a higher susceptibility to be impacted by SARS-CoV-2 infection through ACE2. SARS-CoV-2 increased the expression of IRAK3 and ADRB2, which lead to a higher risk of asthma (Fig. 5B) . Second, decreased levels of L-arginine and L-citrulline were found in SARS-CoV-2 infected patients (50), while it has been shown that higher levels of these metabolites are protective against asthma (49) . L-arginine can be converted to nitric oxide by the nitric oxide synthases, and it was shown that nitric oxide protects against viral infection through multiple potential mechanisms (78) .

Our network proximity results show a strong connection between IBD and COVID-19

( Fig. 4A) . We have also showed IBD-related pathways that can potentially be affected by SARS-CoV-2 infection (Fig. 6B) . However, we should also note that the meta-analysis does not show a significant risk ratio of digestive system disease in COVID-19 patients (Fig. 3B) , while two specific symptoms, abdominal pain and diarrhea, showed increased risks in severe COVID-19 patients (Fig. 6A) . Digestive system disease covers a broad range of gastrointestinal diseases. Finally, we computationally prioritized nearly 3,000 FDA approved/investigational drugs for their potential anti-SARS-CoV-2 effects using network proximity measure and GSEA. A list of 34 repurposable drugs with their reported antiviral profiles are highlighted, among which five drugs are currently in clinical trials (Fig. 7B) . We further explored drug-disease outcome for melatonin using a large-scale COVID-19 registry. We found that among individuals who received testing for SARS-CoV-2, melatonin usage was associated with a 50-60% reduced likelihood of a positive laboratory test result for SARS-CoV-2 (Fig. 7B) . Using user active comparator design, we further discovered that melatonin usage was associated with reduced risk of likelihood of a positive laboratory test result for SARS-CoV-2 compared to ARBs and ACEIs as well. Exogenous melatonin may be of benefit in older patients with COVID-19 given agingrelated reduction of endogenous melatonin and vulnerability of the elderly to lethality of SARS-CoV-2 (79), the latter potentially due to declining immunity, i.e. immunosenescence (80) .

Moreover, melatonin suppresses NLRP3 inflammasome activation induced by cigarette smoking and attenuates pulmonary inflammation (81), not only via reduction of nuclear factor kappa-β p65 (NF-κB p65) and tumor necrosis factor-α (TNF-ɑ) expression, but also via increase in antiinflammatory cytokines such as IL-10 or IL-6 which can also have anti-inflammatory effects (82, 83 course, but may be inconsequential when utilized in severe or end-stage infection.

We acknowledge several potential limitations. First, although we integrated data from multiple sources to build the human interactome and the drug target network, they are still incomplete. Second, this study relied on the SARS-CoV-2 target host genes/proteins data sets, and their quality may influence the performance of our network analysis. Third, the patient-data analysis is retrospective and may have selection bias. Although we performed multiple types of PS-matching observations, residual confounding is possible despite high-dimensional covariate adjustment. For example, carvedilol, approved for both hypertension and heart failure, was identified for potential treatment of COVID-19 by network proximity measure (Fig. 7A) . We d r a f t in this latter group might also have been high. It should therefore be noted that all drugs we identified as therapeutic candidates in this study must be validated using experimental assays and randomized clinical trials before they can be recommended for use in patients with COVID-19.

In conclusion, our study provides a powerful, integrative, network medicine strategy for advancing understanding of COVID-19-associated comorbidities and facilitating the identification of drug candidates for COVID-19. This approach also promises to address the translational gap between genomic studies and clinical outcomes, which poses a significant problem when rapid development of effective therapeutic interventions is critical during a pandemic. From a translational perspective, if broadly applied, the network-medicine tools applied here could prove helpful in developing effective treatment strategies for other complex human diseases as well, including other emerging infectious diseases.

We assembled four SARS-CoV-2 data sets of target host genes/proteins: (1) d r a f t and SARS2-PPI, we combined these data sets as the fifth SARS-CoV-2 data set, which has 460 proteins and is denoted as PanCoV-PPI.

We compiled the disease-associated gene sets from various sources. All databases were accessed on March 26, 2020.

Cancer. The pan-cancer driver genes were retrieved from the Cancer Gene Census (35) . Driver genes for individual cancer types were from a previous study (36) .

Mendelian Inheritance in Man (OMIM) database (84) .

A set of 2,124 ODMGs were retrieved from a previous study (85) .

Cell cycle genes. 910 human cell cycle genes were downloaded from a previous study identified by a genome-wide RNAi screening (86) .

Innate immune genes. 1,031 human innate immunity genes were collected form InnateDB (87) .

diseases. The disease-associated genes/proteins were extracted from the Human Gene Mutation Database (HGMD) (37) . A systematic search was manually performed for each disease using keywords such as disease name, alias, and symptoms to identify the disease terms in the HGMD.

All disease terms were then verified for their relevance. biological process enrichment analyses to reveal the biological relevance and functional pathways of the five SARS-CoV-2 data sets. All functional enrichment analyses were performed using Enrichr (88) .

We calculated the dN/dS ratio (89) and the evolutionary rate ratio (90) as described in our previous study (91) .

The RNA-Seq data (transcripts per million, TPM) of 31 tissues from the GTEx V8 release 

PubMed, Embase and Medrxiv databases were searched for publications as of April 25 th , 2020 (Fig. S13) . The search was limited to English articles describing the demographic and clinical features of SARS-CoV-2 cases. We used the search term ("SARS-COV-2" OR "COVID-19" OR protein-protein interactome are provided in our previous studies (24, 29, 30, 97) .

We used the "closest" network proximity measure throughout this study. For two gene/protein sets and , their "closest" distance was calculated as:

Z h o u e t a l . 2 0 2 0 d r a f t where ( , ) is the shortest distance of and in the human interactome. To evaluate the significance, we performed a permutation test using randomly selected proteins from the whole interactome that were representative of the two protein sets being evaluated in terms of their degree distributions. We then calculated the Z score as:

where and were the mean and standard deviation of the permutation test. All network proximity permutation tests in this study were repeated 1,000 times.

To reveal potential COVID-19 comorbidities, we computed the network proximity of the disease-associated proteins for each disease and the five SARS-CoV-2 data sets. SARS-CoV-2 target proteins with a non-negative tissue specificity in lung were used in the computation. The degree enrichment for protein in a subnetwork was calculated as:

where is the degree of in the subnetwork, is number of nodes in the subnetwork, is the degree in the complete human protein interactome, and is the total number of nodes in the interactome.

Bulk RNA-Seq data sets for asthma patients were retrieved from the NCBI GEO database (https://www.ncbi.nlm.nih.gov/geo/) using the accession number GSE63142 (54) and

GSE130499 (55) . Differential expression of three comparisons, severe vs. control, mild vs. "FindIntegrationAnchors" and "IntegrateData" functions were used to integrate cells from different samples. UMAP was used as the dimension reduction method for visualization. Cell type markers from the original paper were used to label the cell types.

To evaluate whether a drug is closely associated with SARS-CoV-2 target proteins in the human interactome, we gathered the drug-target interaction information from several databases:

DrugBank database (v4.3) (99), Therapeutic Target Database (TTD) (100), PharmGKB database, ChEMBL (v20) (101), BindingDB (102) , and IUPHAR/BPS Guide to PHARMACOLOGY (103) . We included the interactions that have binding affinities Ki, Kd, IC50 or EC50 ≤ 10 μM and a unique UniProt accession number with "reviewed" status. The details for building the experimentally validated drug-target network can be found in our recent studies (24, 29, 30) .

Z h o u e t a l . 2 0 2 0 d r a f t We computed the "closest" network proximity as described before for 2,938 FDA approved or investigational drugs and the five SARS-CoV-2 data sets. For prioritization, we ranked the drugs by their distance to the data sets (D < 2) and Z score (Z < -1.5) from the network proximity analysis. The antiviral profiles of the highlighted drugs were manually curated. COVID-19

related clinical trials were retrieved on May 10, 2020.

The gene set enrichment analysis was conducted as described in our recent work (28) The enrichment score ES was calculated for up-and down-regulated genes separately first. The overall ES was calculated as:

where and were calculated using / and / as: 

We used the institutional review board-approved registry COVID-19 registry data, including outcomes using the institutional review board-approved COVID-19 patient registry.

Pathway and gene ontology (biological process) enrichment analysis results of the SARS-CoV-2 host genes/proteins across five different data sets. We assembled five gene/protein data sets from SARS-CoV-2 host protein-protein interactions, transcriptomics, and proteomics (Table S1) and I 2 statistics were calculated to quantify the heterogeneity among studies. I 2 < 50% was considered as low heterogeneity among studies, 50% < I 2 < 75% was considered as moderate heterogeneity, and I 2 > 75% was considered as high heterogeneity. severity with IL-6 expression levels in patients. Meta-analysis of random effects model was performed using the mean difference in IL-6 (pg/ml). There was a high heterogeneity among these studies (I 2 = 94%, P < 0.001). 

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical course and outcomes of critically with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

China Novel Coronavirus, T. Research, A Novel Coronavirus from Patients with Pneumonia in China

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Ordovas-Montanes, SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process

Understanding Human-Virus Protein-Protein Interactions Using a Human Protein Complex-Based Analysis Framework

Computational network biology: Data, models, and applications

Coronaviruses -drug discovery and therapeutic options

SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Silico Oncology Drug Repositioning and Polypharmacology

Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era

Drug Repurposing: New Treatments for Zika Virus Infection?

Network-based approach to prediction and population-based validation of in silico drug repurposing

Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

A genome-wide positioning systems network algorithm for in silico drug repurposing

Network-based prediction of drug combinations

Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19. arXiv

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19

RhoA/Rho-Kinase in the Cardiovascular System

Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation

Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy

The biology of the ABCA3 lipid transporter in lung health and disease

Abnormal expression of surfactant protein C and lung disease

The trinity of COVID-19: immunity, inflammation and intervention

Association of serum interleukin-6, interleukin-8, and Acute Physiology and Chronic Health Evaluation II score with clinical outcome in patients with acute respiratory distress syndrome

Accuracy of serum interleukin (IL)-6 in sepsis diagnosis: a systematic review and meta-analysis

Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions

Effective treatment of severe COVID-19 patients with tocilizumab

O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5

Metabolomic Endotype of Asthma

L-Citrulline increases nitric oxide and improves control in obese asthmatics

Proteomic and Metabolomic Characterization of COVID-19

Arachidonic acid metabolism: role in inflammation

Arachidonic acid metabolism in inflammatory cells of patients with bronchial asthma

What are leukotrienes and how do they work in asthma?

Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways

BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications

IRAK-M Is Involved in the Pathogenesis of Early-Onset Persistent Asthma

Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors

SARS-CoV-2 productively infects human gut enterocytes

Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management

Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy

Extended haplotype association study in Crohn's disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-kappaB pathway gene, HEATR3

Single Nucleotide Polymorphisms That Increase Expression of the Guanosine Triphosphatase RAC1 Are Associated With Ulcerative Colitis

Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease

Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease

Cefdinir: A Review of its Use in the Management of Mild-to-Moderate Bacterial Infections

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection

MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv

Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with

Evidence for Gastrointestinal Infection of SARS-CoV-2

An association study of asthma and related phenotypes with polymorphisms in negative regulator molecules of the TLR signaling pathway

IL-1 receptor-associated kinase 3 gene (IRAK3) variants associate with asthma in a replication study in the Spanish population

Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects

Functional Genetic Variation in NFKBIA and Susceptibility to Childhood Asthma, Bronchiolitis, and Bronchopulmonary Dysplasia

Nitric oxide and virus infection

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Immunosenescence: emerging challenges for an ageing population

Melatonin alleviates cigarette smoke-induced endothelial cell pyroptosis through inhibiting ROS/NLRP3 axis

Melatonin reduces acute lung injury in endotoxemic rats

Melatonin attenuates ER stress and mitochondrial damage in septic cardiomyopathy: A new mechanism involving BAP31 upregulation and MAPK-ERK pathway

Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders

The orphan disease networks

Genome-scale RNAi profiling of cell division in human tissue culture cells

InnateDB: systems biology of innate immunity and beyond-recent updates and continuing curation

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

Adjusting for selection on synonymous sites in estimates of evolutionary distance

Coevolution reveals a network of human proteins originating with multicellularity

Studying Tumorigenesis through Network Evolution and Somatic Mutational Perturbations in the Cancer Interactome

Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease

Meta-analysis in clinical trials

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data

Database resources of the National Center for Biotechnology Information

Conformational Dynamics and Allosteric Regulation Landscapes of Germline PTEN Mutations Associated with Autism Compared to Those Associated with Cancer

Integrating single-cell transcriptomic data across different conditions, technologies, and species

DrugBank 4.0: shedding new light on drug metabolism

Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information

ChEMBL: a large-scale bioactivity database for drug discovery

BindingDB: a webaccessible database of experimentally determined protein-ligand binding affinities

The IUPHAR/BPS Guide to PHARMACOLOGY: an expertdriven knowledgebase of drug targets and their ligands

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome

Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus

We thank all helpful discussions and critical comments regarding this manuscript from the